First maintenance therapy for COPD in the UK between 2009 and 2012: A retrospective database analysis

npj Primary Care Respiratory Medicine

Volumn 26, Issue , 2016, Pages

  Price, David ^a   Miravitlles, Marc ^b   Pavord, Ian ^c   Thomas, Mike ^d   Wedzicha, Jadwiga ^e   Haughney, John ^a   Bichel, Katsiaryna ^f   West, Daniel ^f  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f Research in Real Life Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PNEUMONIA; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED KINGDOM; CLINICAL PRACTICE; FACTUAL DATABASE; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AGED; BRONCHODILATOR AGENTS; DATABASES, FACTUAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED KINGDOM;

EID: 84994252935     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/npjpcrm.2016.61     Document Type: Article

References (30)

1. Health and Safety Executive. Chronic Obstructive Pulmonary Disease (COPD) in Great Britain (2013). Available at www.hse.gov.uk/statistics/causdis/copd/. Accessed on 11 October 2015.
2. National Institute for Health and Care Excellence. NICE pathways. COPD. Available at http://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease# content=view-node%3Anodes-referral-for-specialist-advice. Accessed on 11 October 2016.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, Available at http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed on 11 October 2016.
4. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Available at http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed on 11 October 2016.
5. Price, D., Yawn, B., Brusselle, G. & Rossi, A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 22, 92-100 (2013).
6. Anton, E. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease? Expert Rev. Respir. Med. 7(2 Suppl), 25-32 (2013).
7. Sabroe, I., Postma, D., Heijink, I. & Dockrell, D. H. The yin and the yang of immunosuppression with inhaled corticosteroids. Thorax 68, 1085-1087 (2013).
8. Jones, R. C., Dickson-Spillmann, M., Mather, M. J., Marks, D. & Shackell, B. S. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir. Res. 9, 62-69 (2008).
9. Corrado, A. & Rossi, A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir. Med. 106, 989-997 (2012).
10. Drivenes, E., Ostrem, A. & Melbye, H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam. Pract. 15, 42 (2014).
11. Jebrak, G. [COPD routine management in France: are guidelines used in clinical practice?]. Rev. Mal. Respir. 27, 11-18 (2010).
12. Jochmann, A. et al. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med. Wkly. 140 (w13053), 1-8 (2010).
13. Price, D. et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int. J. Chron. Obstruct. Pulmon. Dis. 9, 889-904 (2014).
14. Di Martino, M. et al. Use patterns of long-acting bronchodilators in routine COPD care: the OUTPUL study. COPD 11, 414-423 (2014).
15. Fitch, K., Iwasaki, K., Pyenson, B., Plauschinat, C. & Zhang, J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr. Med. Res. Opin. 27, 1425-1429 (2011).
16. Miravitlles, M. et al. Use of spirometry and patterns of prescribing in COPD in primary care. Respir. Med. 101, 1753-1760 (2007).
17. White, P., Thornton, H., Pinnock, H., Georgopoulou, S. & Booth, H. P. Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study. PLoS ONE 8, e75221 (2013).
18. Brusselle, G. et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 2207-2217 (2015).
19. Kerkhof, M., Freeman, D., Jones, R., Chisholm, A. & Price, D. B. Predicting frequent COPD exacerbations using primary care data. Int. J. Chron. Obstruct. Pulmon. Dis. 10, 2439-2450 (2015).
20. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007).
21. Loke, Y. K., Cavallazzi, R. & Singh, S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66, 699-708 (2011).
22. Singh, S. & Loke, Y. K. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr. Opin. Pulm. Med. 16, 118-122 (2010).
23. Agusti A. et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur. Respir. J. 42, 36-646 (2013).
24. DiSantostefano, R. L. et al. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PLoS ONE 9, e97149 (2014).
25. Mattishent, K. et al. Meta-review: adverse effects of inhaled corticosteroids relevant to older patients. Drugs 74, 539-547 (2014).
26. Kew, K. M. & Seniukovich, A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 3, CD010115 (2014).
27. Suissa, S., Patenaude, V., Lapi, F. & Ernst, P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 68, 1029-1036 (2013).
28. Lee, T. A. & Weiss, K. B. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 169, 855-859 (2004).
29. Rogliani, P., Calzetta, L., Segreti, A., Barrile, A. & Cazzola, M. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol. 51, 933-940 (2014).
30. Slatore, C. G., Bryson, C. L. & Au, D. H. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am. J. Med. 122, 472-478 (2009).